Br J Haematol 194:240251
Well, they are obviously the same medication but how you take it makes ALL of the difference
Horm Metab Res (1994) 26:4138
![jens juul holst glp 1 New book by Professor about the history of GLP-1 Find out more info about the book and book reception below "In India, [#GLP-1 receptor agonists]](https://mva.org/wp-content/uploads/2025/04/Jens-Juul-700x350-1.jpg)
If They Injected the Product and Have These Symptoms ER care is appropriate for: redness, warmth, or swelling at the injection site fever streaking up the limb worsening pain Unregulated injectable peptides carry risks of: bacterial contamination sepsis injection-site abscess transmission of bloodborne infections (if needles were shared) When Its Reasonable to See Their Regular Physician The teen can usually start with their primary care provider within the next day or two if: They have no emergency symptoms above AND They are acting normally, with stable mood and behavior AND Their symptoms are mild and nonspecific, such as: mild headache mild nausea mild fatigue trouble sleeping mild anxiety concerns about possible side effects but currently stable When to Call the On-Call Doctor, Advice Nurse, or Poison Control If youre unsure, or if your teen has symptoms that are concerning but not obviously emergent: new irritability, but not out of control elevated heart rate but no chest pain mild tremors or shakiness moderate anxiety thats above their baseline but not severe trouble sleeping or restlessness not typical for them emotional changes They can help decide whether you need same-day primary care, urgent care, or emergency evaluation
![jens juul holst glp 1 New book by Professor about the history of GLP-1 Find out more info about the book and book reception below "In India, [#GLP-1 receptor agonists]](https://content.ugeskriftet.dk/sites/default/files/2023-02/JENS_JUUL_HOLST_2_2022_krediteres%20som_foto%20Lars%20Svankj%C3%A6r%20Videns.jpg)
Products for Men Bremelanotide/Oxytocin/Tadalafil Consider this one the trifecta
With regard to nicotine use disorder, a randomized trial evaluating dulaglutide for smoking cessation found that abstinence rates at 12 weeks did not differ significantly between the dulaglutide and placebo groups (Lengsfeld et al., 2023)